Lauren M. Green

Researchers are hoping that a new nationwide effort to encourage patients to share their tumor samples and clinical information will lead to new discoveries and better treatments.

Intraperitoneal chemotherapy is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer.

West Cancer Center researchers developed a best nursing practice protocol for titration of fentanyl sublingual spray, which is the most recently approved transmucosal immediate-release fentanyl formulation.

When oncology nurses move proactively to learn more about and use proven effective green-lighted interventions like exercise and muscle relaxation in their daily practice, it can go a long way.

Developing a skin rash as a result of EGFR-inhibitor targeted therapy often signals that the drug is working, but for patients who experience these serious dermatologic adverse events, it may become so intolerable that they will scale back or even discontinue anticancer medications that could prolong their survival.

Chest radiotherapy to treat a childhood cancer is a well-established risk factor for developing breast cancer in adulthood

An expert panel has developed clinical practice guidelines for the management of head and neck cancer survivors.

A study involving nearly 30,000 patients diagnosed with early-stage breast cancer has found that up to 60% of these women received imaging tests such as CT, bone, and PET scans that were not medically justified, contrary to national guidelines.

Although patients and survivors often complain of “chemobrain” during and after their cancer treatment, it turns out that there are multiple factors behind the cognitive decline many survivors experience.

For patients with advanced midgut neuroendocrine tumors, the peptide receptor radionuclide therapy Lu-Dotatate continues to confer a major therapeutic benefit, reducing the risk of disease progression or death by 79% and signaling an improvement in overall survival as well.

Aspirin’s benefits may now extend to reducing the risk of deadly prostate cancer, according to the results of an observational study which found that previously undiagnosed men who took regular aspirin had a 24% lower risk of developing a lethal form of the disease.

Patient reports of their experiences with taking either tamoxifen or anastrozole can help clinicians decide which one to recommend to individual women, new research has found.

Women who opt for breast-conserving therapy and radiation to treat their early-stage breast cancer are about 20% more likely to be alive after 10 years compared with their counterparts who had mastectomy.

A follow-up analysis of the benefits of adding denosumab to aromatase inhibitor therapy has found that the agent not only helps to prevent fractures, it reduces the risk of recurrence and death in postmenopausal women with HR-positive breast cancer.

The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an effort that poses both opportunities and challenges.

A pilot study of the efficacy of CAR T-cell therapy in patients with EGFRvIII-positive glioblastoma multiforme (GBM) has generated encouraging findings.

As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.

While the prognosis remains good for individuals with HPV-positive oropharyngeal cancers, the incidence of these cancers continues to rise, and researchers are currently seeking less intense treatment options that are equally effective but not as toxic for patients.

The landscape for the diagnosis and treatment of polycythemia vera (PV) is changing, and that's good news for patients and practitioners who can look to improvements ahead.

Adjuvant radiation therapy was shown to improve overall survival and disease-specific survival following lumpectomy for elderly women with early stage triple-negative breast cancer.

Survival for patients with metastatic squamous non–small cell lung cancer whose tumors were positive for EGFR copy number as determined by FISH analysis tended to be better when the EGFR antibody necitumumab was added to their conventional chemotherapy.

Women with ovarian cancer who experienced an average dose reduction of ≤85% had a 35% higher mortality risk than those who received normal dosing.

Despite the overall rate increase in breast-conserving therapy among women with early-stage breast cancer, economic and geographic factors have left some patients behind.

Physicians will now have a new option for some patients who have run out of them, but whose tumors have a genomic variation matching a drug target that is FDA-approved for a different cancer.

Elective neck dissection performed at the same time patients have surgery for early-stage, node-negative, oral squamous cell cancer significantly improved overall survival and reduced the risk of death and recurrence when compared with a watchful waiting approach.

The first study to compare the efficacy and safety of tamoxifen versus anastrozole in women treated for ductal carcinoma in situ suggests that anastrozole may be the better choice for preventing the escalation of DCIS into invasive cancer.

Patients with relapsed indolent non-Hodgkin lymphoma experienced a doubling of progression-free survival when treated with a combination of the anti-CD20 agent obinutuzumab and bendamustine.

In a multisite study offering the largest experience to date of how immunotherapy can be deployed in patients with head and neck cancer, the anti-PD-1 antibody pembrolizumab produced broad and durable responses in patients with advanced disease.

To assess the impact of additional screening, Jean M. Weigert, MD, FACR, head of breast imaging for the Hospital of Central Connecticut, conducted a retrospective chart review to see how well it worked in detecting cancers in women with dense breasts during the first 4 years of implementation statewide.

For those with a history of non-melanoma skin cancer, reducing their risk of recurrence can be as simple as taking the vitamin B3 pill nicotinamide.